Joachim Gullbo

4.9k total citations
100 papers, 4.0k citations indexed

About

Joachim Gullbo is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Joachim Gullbo has authored 100 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Molecular Biology, 40 papers in Oncology and 20 papers in Cancer Research. Recurrent topics in Joachim Gullbo's work include Peptidase Inhibition and Analysis (21 papers), Ubiquitin and proteasome pathways (13 papers) and Glycosylation and Glycoproteins Research (10 papers). Joachim Gullbo is often cited by papers focused on Peptidase Inhibition and Analysis (21 papers), Ubiquitin and proteasome pathways (13 papers) and Glycosylation and Glycoproteins Research (10 papers). Joachim Gullbo collaborates with scholars based in Sweden, United States and Germany. Joachim Gullbo's co-authors include Rolf Larsson, Peter Nygren, Malin Wickström, Ulf Göransson, Lars Bohlin, Mårten Fryknäs, Per Claeson, Linda Rickardson, Stig Linder and Pádraig D’Arcy and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Joachim Gullbo

98 papers receiving 3.9k citations

Peers

Joachim Gullbo

ONCOL

IMMUN

Angela Nebbioso Italy

Dajun Yang China

Jiang‐Jiang Qin China

Claudio Pisano Italy

Haiying Chen United States

Christopher L. Morton United States

Stefania Sarno Italy

Yiqing Yang China

Jeffrey M. Besterman United States

Panayotis Pantazis United States

Angela Nebbioso Italy

Joachim Gullbo

4.0k ×1.4

840 ×0.8

ONCOL

192 ×0.3

396 ×0.8

IMMUN

482 ×1.0

Citations per year, relative to Joachim Gullbo Joachim Gullbo (= 1×) peers Angela Nebbioso

Countries citing papers authored by Joachim Gullbo

Since Specialization

Citations

This map shows the geographic impact of Joachim Gullbo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joachim Gullbo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joachim Gullbo more than expected).

Fields of papers citing papers by Joachim Gullbo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joachim Gullbo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joachim Gullbo. The network helps show where Joachim Gullbo may publish in the future.

Co-authorship network of co-authors of Joachim Gullbo

This figure shows the co-authorship network connecting the top 25 collaborators of Joachim Gullbo. A scholar is included among the top collaborators of Joachim Gullbo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joachim Gullbo. Joachim Gullbo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Byrgazov, Konstantin, Thomas Lind, Annica J. Rasmusson, et al.. (2021). Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes. Bone Reports. 15. 101098–101098. 3 indexed citations

Perego, Paola, Karthik Selvaraju, Laura Gatti, et al.. (2019). Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15. PLoS ONE. 14(10). e0223807–e0223807. 10 indexed citations

Wang, Xin, Magdalena Mazurkiewicz, Ellin‐Kristina Hillert, et al.. (2016). The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Scientific Reports. 6(1). 26979–26979. 133 indexed citations

Zhang, Xiaonan, et al.. (2016). Eradicating Quiescent Tumor Cells by Targeting Mitochondrial Bioenergetics. Trends in cancer. 2(11). 657–663. 16 indexed citations

Wickström, Malin, et al.. (2016). In vitro and in vivo activity of melflufen (J1) in lymphoma. BMC Cancer. 16(1). 263–263. 16 indexed citations

Fryknäs, Mårten, Xiaonan Zhang, Ulf Bremberg, et al.. (2016). Iron chelators target both proliferating and quiescent cancer cells. Scientific Reports. 6(1). 38343–38343. 57 indexed citations

Mohell, Nina, Jessica Alfredsson, Åsa Fransson, et al.. (2015). APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death and Disease. 6(6). e1794–e1794. 151 indexed citations

Wu, Xuping, Linda Sooman, Malin Wickström, et al.. (2013). Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro. Molecular Cancer Therapeutics. 12(8). 1526–1536. 15 indexed citations

Wickström, Malin, Peder Fredlund Fuchs, Mårten Fryknäs, et al.. (2013). The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo. Biochemical Pharmacology. 86(7). 888–895. 31 indexed citations

10.

Fryknäs, Mårten, Joachim Gullbo, Xin Wang, et al.. (2013). Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance. BMC Cancer. 13(1). 374–374. 8 indexed citations

11.

Wu, Xuping, Håkan Hedman, Michael Bergqvist, et al.. (2011). Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity. Acta Oncologica. 51(1). 69–76. 17 indexed citations

12.

Dyrager, Christine, Malin Wickström, Maria Fridén‐Saxin, et al.. (2011). Inhibitors and promoters of tubulin polymerization: Synthesis and biological evaluation of chalcones and related dienones as potential anticancer agents. Bioorganic & Medicinal Chemistry. 19(8). 2659–2665. 61 indexed citations

13.

Haglund, Caroline, Anna Åleskog, Peter Nygren, et al.. (2011). In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues. Cancer Chemotherapy and Pharmacology. 69(3). 697–707. 27 indexed citations

14.

Hallböök, Heléne, Jenny Felth, Anna Eriksson, et al.. (2011). Ex Vivo Activity of Cardiac Glycosides in Acute Leukaemia. PLoS ONE. 6(1). e15718–e15718. 25 indexed citations

15.

Wickström, Malin, Kristina Viktorsson, Lovisa Lundholm, et al.. (2010). The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. Biochemical Pharmacology. 79(9). 1281–1290. 51 indexed citations

16.

Wickström, Malin, Rolf Larsson, Peter Nygren, & Joachim Gullbo. (2010). Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Science. 102(3). 501–508. 296 indexed citations

17.

Herrmann, Anders, Erika Svangård, Per Claeson, et al.. (2006). Key role of glutamic acid for the cytotoxic activity of the cyclotide cycloviolacin O2. Cellular and Molecular Life Sciences. 63(2). 235–245. 91 indexed citations

18.

Gullbo, Joachim, Henrik Lövborg, Sumeer Dhar, et al.. (2004). Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828. Anti-Cancer Drugs. 15(1). 45–54. 4 indexed citations

19.

Gullbo, Joachim, Malin Wickström, Hans Ehrsson, et al.. (2003). Activity of Hydrolytic Enzymes in Tumour Cells is a Determinant for Anti-tumour Efficacy of the Melphalan Containing ProdrugJ1. Journal of drug targeting. 11(6). 355–363. 41 indexed citations

20.

Lövborg, Henrik, et al.. (2001). Modulation of cell death and metabolic effects by 3-aminobenzamide in U-937 GTB cells exposed to CHS 828. Biochemical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact